Crescent Biopharma, Inc. cash flow to debt ratio of -4.35K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Crescent Biopharma, Inc.'s free cash flow has decreased 132.90% from $-31.11M last year to $-72.45M, signaling decreasing performance

Crescent Biopharma, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Crescent Biopharma, Inc.'s debt has increased relative to shareholder equity from -2.42 last year to 0.01 today, signaling weakened financials

Crescent Biopharma, Inc. has a net cash position, so leverage is healthy.

Crescent Biopharma, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Crescent Biopharma, Inc. has insufficient data to evaluate this check.

Crescent Biopharma, Inc.'s short-term assets of $236.66M exceed its short-term liabilities of $36.07M

Crescent Biopharma, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Crescent Biopharma, Inc.'s return on equity of -97.77%, is lower than 15.00%, indicating bad performance

Crescent Biopharma, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Crescent Biopharma, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Crescent Biopharma, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Crescent Biopharma, Inc. has negative free cash flow, indicating cash burn

Crescent Biopharma, Inc.'s yearly earnings has decreased 217.25% since last year from $-48.52M to $-153.94M, signaling decreasing performance

Crescent Biopharma, Inc.'s yearly revenue has increased % since last year from $0.00 to $10.84M, signaling increasing performance

ROIC -102.29% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Crescent Biopharma, Inc.'s 3-year revenue CAGR of 424.86% is positive, indicating growing revenue over the past 3 years

Crescent Biopharma, Inc. had revenue growth in only 1 out of 5 years, indicating inconsistent revenue performance

Crescent Biopharma, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Crescent Biopharma, Inc. has insufficient data to evaluate this check.

Crescent Biopharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Crescent Biopharma, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Crescent Biopharma, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Crescent Biopharma, Inc. is overvalued relative to its fair value price of -3.14K based on Earnings Fair Value model

Crescent Biopharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Crescent Biopharma, Inc. has a price-to-book ratio of 3.24x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Crescent Biopharma, Inc. has a price-to-sales ratio of 44.53x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue